10 Ufa residents are participating in trials of Russian drug against COVID-19

IMPORT Сервисный

Clinical trials of a drug against COVID-19 have begun in Bashkiria, Vesti Bashkortostan reports. The Levilimab intended for the treatment of the new type of coronavirus infection began to be tested in three Russian centers. One of them is the clinic of Bashkir State Medical University (BSMU).

Now the first stage of testing is taking place, in which 10 Ufa residents are taking part. The drug is intended for those who are already sick. Subcutaneous injection is administered once. The results of the first tests will be known in June, after which the second stage of testing will begin.

"The first stage of the clinical trial of the drug will be completed in early June," said Bulat Bakirov, head of the department of hospital therapy at BSMU. "Then there will be final information on the effectiveness of this drug. Therefore, I am sure that we will receive a drug for the treatment of patients in the near future."

#drug #coronavirus

Join us for more and faster updates on our social media.:

Rubrics

Phone

Office: +7(347) 250-05-07 Advertising office: +7(347) 250-11-11 Editors office: +7(347) 250-07-28 Cooperation: +7(347) 250-06-14

inf@bashinform.ru

Address

450077, Ufa, Kirov street, 45

© 1992-2026 Bashinform News Agency JSC. Mass Media Registration Certificate No. TU 02-01609 dated September 25, 2017, issued by the Office of the Federal Service for Supervision of Communications, Information Technology and Mass Media for the Republic of Bashkortostan.

All information and content posted on the website www.bashinform.ru are protected by international and Russian copyright and related rights legislation. All reports by the Bashinform News Agency are intended for users over 18 years of age.

When reprinting or quoting, a reference to Bashinform News Agency is mandatory. For online publications and social media, a direct active hyperlink is required. Using the Bashinform News Agency logo for purposes not related to the agency when reprinting or quoting is permitted only with the written permission of JSC Bashinform News Agency.